Shenzhen Salubris Pharmaceuticals’ Fotagliptin Receives NMPA Approval for Type 2 Diabetes Treatment
Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294), a pharmaceutical company based in China, has announced...
Roche’s Alecensa Secures NMPA Approval as Adjuvant Therapy for Early-Stage NSCLC
Roche (SWX: RO), the Swiss pharmaceutical giant, has announced that it has received an additional...
Immorna Earns FDA Approval for Phase I/II Clinical Trial of Self-Replicating RNA Cancer Therapy
Immorna (Hangzhou) Biotechnology, a biotech company specializing in mRNA-based vaccines and located in Hangzhou, has...
Novo Nordisk’s Esperoct Receives NMPA Approval, First Long-Acting Factor VIII for Hemophilia A in China
The National Medical Products Administration (NMPA) has granted approval to Novo Nordisk (NYSE: NVO), a...
Xinzeyuan Medical Technology Secures Over RMB 100 Million in Series B Financing
Xinzeyuan Medical Technology Co., Ltd, a Hangzhou-based micro invasive medical device supply chain platform, has...
Innovent Biologics and IASO Biotherapeutics Amend Partnership, Focusing on CAR-T Therapy Fucaso
Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced a...
PharmaEssentia’s Besremi Receives Approval for Polycythemia Vera Treatment in China
PharmaEssentia Corporation (TPE: 6446, FRA: 8Z1), a biopharmaceutical company based in Taiwan, has announced that...
Haisco Pharmaceutical’s Crisugabalin Gains NMPA Approval for Post-Herpes Neuralgia Treatment
Haisco Pharmaceutical Group Co., Ltd (SHE: 002653), a leading pharmaceutical company based in China, has...
Hinova Pharmaceuticals’ HP537 Receives FDA Approval for Phase I/II Clinical Trial in Hematologic Malignancies
Hinova Pharmaceuticals Inc. (SHA: 688302), a biotech company based in Chengdu, has announced that it...
Easton Pharmaceutical Receives NMPA Approval for Generic Oxcarbazepine
Easton Pharmaceutical Co., Ltd (SHA: 688513), based in Chengdu, has announced that it has received...
Amoytop Biotech’s Peginterferon α-2b Receives NMPA Approval for Primary Thrombocytosis Clinical Trial
Amoytop Biotech Co. Ltd (SHA: 688278), based in Xiamen, has announced that it has received...
Daiichi Sanky’s Mirogabalin Gets Green Light from China for Diabetic Neuropathic Pain
Daiichi Sanky (TYO: 4568), a pharmaceutical company based in Japan, has announced that it has...
Antengene’s Xpovio Secures NMPA Approval for R/R Diffuse Large B-Cell Lymphoma
Antengene Corp., Ltd (HKG: 6996), a biopharmaceutical company based in China, has announced that it...
Sirnaomics’ STP122G Achieves Phase I Milestone with Positive Interim Data for Anticoagulation Treatment
Sirnaomics Ltd (HKG: 2257) has announced the completion of the Phase I second sequence for...
Kindstar Global and MGI Tech Co., Ltd. Form Partnership to Establish Multi-Omics Service Center in China
Kindstar Global (HKG: 9960), a biopharmaceutical company based in China, has announced a strategic partnership...
Pharmaceutical Giants Face UK Industry Code Breach Allegations, Including Novartis and Pfizer
Several multinational pharmaceutical corporations have been reprimanded for violating the UK’s Prescription Medicines Code, a...
Roche’s Tiragolumab Misses Primary Endpoints in NSCLC Trial, Study Halted
Roche (SWX: ROG; SWX: RO; OTCMKTS: RHHBY), the Swiss pharmaceutical giant, has announced that a...
Medigene AG Secures Chinese Patent for TCR-T Therapy Targeting NY-ESO-1 and LAGE 1a
Medigene AG (ETR: MDG1), a biopharmaceutical company based in Germany, has announced that it has...
MicroPort Scientific Corp’s Subsidiaries Forecast Significant H1 2024 Revenue Growth
MicroPort Scientific Corp (HKG: 0853), a leading medical device company, has seen its subsidiaries Shanghai...
Singlera Genomics Secures Over RMB 100 Million in Strategic Financing to Boost R&D and Commercialization
Singlera Genomics Inc., a genetic testing and molecular diagnostics company with operations in San Diego,...